Catalyst Pharmaceuticals is a biopharmaceutical company that develops and markets drugs for the treatment of neurological and neuromuscular diseases. The company serves customers all across the United States. They employ 76 workers across the globe with a total market cap of $381.42 as of this writing. CPRX currently trading at $3.68 per share as of this article, generates approximately $102 million in revenue on an annual basis.
With $31.88 Million in net profit, translating into $0.30 of earnings on a per share basis, this company has some upside value worth noting. Catalyst Pharmaceuticals has received 4 Buy ratings in the past 180 days with upside price targets in the 100% plus range of its current trading price. Last quarter CPRX posted a net margin of 60.48% and had a trailing 12 month return on Equity (ROE) of 35%
Covid-19 Impact on Catalyst Pharmaceuticals
CPRX was trading at $3.52 per share right around march 11th, 2020 when Covid-19 reached pandemic status according to the WHO (World Health Organization) but traded as low as $2.61. The stock’s price as of this writing is $3.68 per share which is almost a 4% increase from that level, however the stock has traded as high as $5 in the past year. From low to high we see an increase of about 41%.
Earnings Coming Up Soon
In the third quarter of 2020, the company reported that total sales fell 5.1% over the same period last year, and net profit increased 218.0% over the same period last year. The increase in net income is primarily due to one-time benefits of deferred tax assets 2. The company reported EPS of $.11 beating the estimate of $.10. Revenue fell to $29.32 Million for the quarter compared to the expectation of analysts which was 31.22 Million. The next Earnings date for CPRX is Monday March 15, 2021.
